Cargando…

Effects of renal denervation therapy on cardiac function and malignant arrhythmia in patients with reduced left ventricular ejection fraction and narrow QRS complexes treated with implantable cardioverter defibrillator

Objective : The purpose of this study was to explore the effects of renal denervation (RDN) on cardiac function and malignant arrhythmia in patients with reduced left ventricular ejection fraction (HFrEF) and narrow QRS treated with an implantable cardioverter defibrillator (ICD). Methods: A total o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Wei, Xu, You-Long, Gao, Jun-Qing, Shen, Deng, Li, Min, Fa, Jing-Jing, Zhang, Ying, Wang, Rui, Hou, Shu-Xin, Hu, Wen-Ying, Jin, Hui-Gen, Liu, Zong-Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Physiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9412050/ https://www.ncbi.nlm.nih.gov/pubmed/36035484 http://dx.doi.org/10.3389/fphys.2022.938486

Ejemplares similares

Selection of patients eligible for implantable cardioverter defibrillator: beyond left ventricular ejection fraction
por: Rizzello, Vittoria
Publicado: (2022)

Evolution of extravascular implantable cardioverter-defibrillator therapy for ventricular arrhythmias
por: Römers, Hans, et al.
Publicado: (2022)

Left ventricular diastolic and systolic dyssynchrony and dysfunction in heart failure with preserved ejection fraction and a narrow QRS complex
por: Liu, Shuang, et al.
Publicado: (2018)

Performance of an automated external cardioverter defibrillator for inhospital ventricular malignant arrhythmia
por: Timerman, S, et al.
Publicado: (2003)

Relationship between right and left ventricular function in candidates for implantable cardioverter defibrillator with low left ventricular ejection fraction
por: Jimenez-Juan, Laura, et al.
Publicado: (2017)

Association between implanted cardioverter-defibrillators and mortality for patients with left ventricular ejection fraction between 30% and 35%
por: Wasfy, Jason H, et al.
Publicado: (2023)

Fragmented QRS as a Predictor of Appropriate Implantable Cardioverter-defibrillator Therapy
por: Apiyasawat, Sirin, et al.
Publicado: (2014)

Strategies to Reduce Recurrent Shocks Due to Ventricular Arrhythmias in Patients with an Implanted Cardioverter-Defibrillator
por: Back, Steven H, et al.
Publicado: (2019)

Physical activity is reduced prior to ventricular arrhythmias in patients with a wearable cardioverter defibrillator
por: Burch, Ashley E., et al.
Publicado: (2019)

Impact of Myocardial Bridge on Life‐Threatening Ventricular Arrhythmia in Patients With Implantable Cardioverter Defibrillator
por: Okada, Kozo, et al.
Publicado: (2020)

Ventricular arrhythmias among patients with implantable cardioverter‐defibrillator during the COVID‐19 pandemic
por: Malanchini, G., et al.
Publicado: (2021)

Diffuse myocardial fibrosis associates with incident ventricular arrhythmia in implantable cardioverter defibrillator recipients
por: Olausson, Eric, et al.
Publicado: (2023)

Impact of cardiovascular magnetic resonance assessment of ejection fraction on eligibility for implantable cardioverter defibrillators
por: Joshi, Subodh B, et al.
Publicado: (2011)

Efficacy of an implantable cardioverter-defibrillator in patients with diabetes and heart failure and reduced ejection fraction
por: Rørth, Rasmus, et al.
Publicado: (2019)

Magnetic Resonance Assessment of Ejection Fraction Versus Echocardiography for Cardioverter-Defibrillator Implantation Eligibility
por: Schiau, Călin, et al.
Publicado: (2021)

The Effect of Sacubitril/Valsartan on Device Detected Arrhythmias and Electrical Parameters among Dilated Cardiomyopathy Patients with Reduced Ejection Fraction and Implantable Cardioverter Defibrillator
por: Russo, Vincenzo, et al.
Publicado: (2020)

Rate of Recovery of Left Ventricular Ejection Fraction in a Real-World Population of Patients Receiving a Wearable Cardioverter Defibrillator
por: Abney, Lon, et al.
Publicado: (2021)

Main air pollutants and ventricular arrhythmias in patients with implantable cardioverter-defibrillators: A systematic review and meta-analysis
por: Yang, Hong-Jie, et al.
Publicado: (2017)

Predictive value of gamma-glutamyltransferase for ventricular arrhythmias and cardiovascular mortality in implantable cardioverter-defibrillator patients
por: Zhou, You, et al.
Publicado: (2019)

Myocardial Scar Characterization and Future Ventricular Arrhythmia in Patients With Ischemic Cardiomyopathy and an Implantable Cardioverter-Defibrillator
por: Noordman, Alwin B. P., et al.
Publicado: (2021)

Sex‐specific differences in outcome and risk stratification of ventricular arrhythmias in implantable cardioverter defibrillator patients
por: van der Lingen, Anne‐Lotte C.J., et al.
Publicado: (2021)

Integrated approach for smart implantable cardioverter defibrillator (ICD) device with real time ECG monitoring: use of flexible sensors for localized arrhythmia sensing and stimulation
por: Puri, Munish, et al.
Publicado: (2013)

Management of hemodynamically stable wide QRS complex tachycardia in patients with implantable cardioverter defibrillators
por: Regoli, François D., et al.
Publicado: (2023)

Implantable cardioverter defibrillator as a treatment for massive left ventricular fibroma-induced ventricular arrhythmia in a child
por: Choi, In Su, et al.
Publicado: (2021)

Longitudinal changes in intracardiac repolarization lability in patients with implantable cardioverter-defibrillator
por: Guduru, Abhilash, et al.
Publicado: (2013)

Use of the Wearable Cardioverter‐Defibrillator Among Patients With Myocarditis and Reduced Ejection Fraction or Ventricular Tachyarrhythmia: Data From a Multicenter Registry
por: El‐Battrawy, Ibrahim, et al.
Publicado: (2023)

Comorbid Hypertension Reduces the Risk of Ventricular Arrhythmia in Chronic Heart Failure Patients with Implantable Cardioverter-Defibrillators
por: Huang, Hao, et al.
Publicado: (2022)

Ventricular tachycardia as presenting arrhythmia as a determinant of appropriate implantable cardioverter-defibrillator therapy in secondary prevention
por: Noordman, A B P, et al.
Publicado: (2023)

Association left ventricular lead and ventricular arrhythmias after upgrade to cardiac resynchronization therapy in patients with implantable cardioverter defibrillators
por: Kawamura, Mitsuharu, et al.
Publicado: (2019)

Potential clinical impact of cardiovascular magnetic resonance assessment of ejection fraction on eligibility for cardioverter defibrillator implantation
por: Joshi, Subodh B, et al.
Publicado: (2012)

Publisher Correction to: Efficacy of an implantable cardioverter-defibrillator in patients with diabetes and heart failure and reduced ejection fraction
Publicado: (2020)

Left Ventricular Wall Stress Is Sensitive Marker of Hypertrophic Cardiomyopathy With Preserved Ejection Fraction
por: Zhao, Xiaodan, et al.
Publicado: (2018)

Interaction between electrical storm and left ventricular ejection fraction as predictors of mortality in patients with implantable cardioverter defibrillator: A Chinese cohort study
por: Zhai, Zhengqin, et al.
Publicado: (2022)

Implantable cardioverter-defibrillator placement among patients with left ventricular ejection fraction ≤35 % at least 40 days after acute myocardial infarction
por: Judson, Gregory L., et al.
Publicado: (2022)

Relationship of Transmural Variations in Myofiber Contractility to Left Ventricular Ejection Fraction: Implications for Modeling Heart Failure Phenotype With Preserved Ejection Fraction
por: Dabiri, Yaghoub, et al.
Publicado: (2018)

Thoracoscopic Left Cardiac Sympathetic Denervation for a Patient with Catecholaminergic Polymorphic Ventricular Tachycardia and Recurrent Implantable Cardioverter-Defibrillator Shocks
por: Yu, Woo-Sik, et al.
Publicado: (2015)

Does defibrillation threshold increase as left ventricular ejection fraction decreases?
por: Val-Mejias, Jesus E., et al.
Publicado: (2010)

Implantable Cardioverter-defibrillator Use in Structural Heart Disease: Narrowing the Playing Field
por: Ellis, Christopher R.
Publicado: (2018)

Improving the appropriateness of sudden arrhythmic death primary prevention by implantable cardioverter-defibrillator therapy in patients with low left ventricular ejection fraction. Point of view
por: Disertori, Marcello, et al.
Publicado: (2016)

Absence of left bundle branch block and blood urea nitrogen predict improvement in left ventricular ejection fraction in patients with cardiomyopathy and wearable cardioverter defibrillators
por: Mehta, Nikhil A., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2d4kc20qseb93o1fnc3uto43er